1. WHO. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6: 35–47.
2. The hepatitis C virus life cycle as a target for new antiviral therapies;Pawlotsky;Gastroenterology,2007
3. The way forward in HCV treatment—finding the right path;Manns;Nat Rev Drug Discov,2007
4. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon alfa-2a with or without ribavirin: Further interim analysis results of the PROVE2 study;Dusheiko;J Hepatol,2008
5. Schering-Plough. Top-line results of boceprevir phase II study showed high rate of sustained response (SVR) in genotype 1 treatment-naı¨ve hepatitis C patients. Available from: http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=1182855. Accessed September 19, 2008.